AYTU - Aytu BioScience, Inc.
| Previous Close | 1.0400 |
| Open | 1.0600 |
| Bid | 1.10 x 1800 |
| Ask | 1.12 x 1100 |
| Day's Range | 1.0200 - 1.0800 |
| 52 Week Range | 0.6800 - 37.4000 |
| Volume | 79,788 |
| Avg. Volume | 329,825 |
| Market Cap | 13.258M |
| Beta (3Y Monthly) | 4.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.85 |
| Earnings Date | Feb 7, 2018 - Feb 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- ACCESSWIRE•9 days ago
Aytu BioScience Reports 71% Revenue Growth in Q2 FY19
Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE / February 7, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products ...
- ACCESSWIRE•16 days ago
Aytu BioScience to Report Fiscal Second Quarter 2019 Results and Business Update
Live Conference Call and Webcast Scheduled for February 7, 2019, at 9:00 a.m. ET ENGLEWOOD, CO / ACCESSWIRE / January 31, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company ...
- ACCESSWIRE•last month
Aytu BioScience Announces U.S. Field Sales Launch of Tuzistra(R) XR
Tuzistra XR Enters the $3 Billion Cough and Cold Market, with 30-35 Million Prescriptions Written Annually Nationwide Field Promotion Begins for Tuzistra XR, Only 12-Hour Codeine-Based Antitussive, 2-3 ...
- ACCESSWIRE•last month
Aytu BioScience Provides Natesto(R) Commercial Update for the Quarter Ending December 31, 2018, Reports 27% Prescription Growth and Expansion of Natesto(R) Direct Program
Natesto Total Prescriptions Increased 27% and Refill Prescriptions Increased 52% Sequentially ENGLEWOOD, CO / ACCESSWIRE / January 10, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical ...
- ACCESSWIRE•2 months ago
Aytu BioScience Announces Commercial Availability of Tuzistra(R) XR (codeine polistirex and chlorpheniramine polistirex) oral suspension
Nationwide availability for the first and only codeine-based, extended-release, oral-suspension cough/cold treatment in U.S. ENGLEWOOD, CO / ACCESSWIRE / December 6, 2018 / Aytu BioScience, Inc. (NASDAQ: ...
- ACCESSWIRE•2 months ago
Aytu BioScience Provides Webcast Information for 2018 LD Micro Conference Presentation
ENGLEWOOD, CO / ACCESSWIRE / December 4, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today provided webcast information for the Company's upcoming presentation at the 11th Annual LD Micro Main Event investor conference. Josh Disbrow, Aytu BioScience's Chief Executive Officer and David Green, Aytu BioScience's Chief Financial Officer, will be presenting at the conference on Wednesday, December 5, 2018 at 9:00 am PT/12:00 pm ET at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
- ACCESSWIRE•2 months ago
Aytu BioScience Announces Appointment of Two New Directors, Steven Boyd and Ketan Mehta
ENGLEWOOD, CO / ACCESSWIRE / December 3, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced two new appointments to the Company's board of directors. Ketan Mehta, Founder and Chief Executive Officer of Tris Pharma joined the board effective November 30, 2018. Steven Boyd, Founder and Chief Investment Officer of Armistice Capital, is expected to be appointed to the board of directors at an upcoming board meeting in the first calendar quarter of 2019.
- ACCESSWIRE•3 months ago
Aytu BioScience Announces Closing of $5M Investment from Armistice Capital
ENGLEWOOD, CO / ACCESSWIRE / November 30, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the closing of a strategic investment in the company by Armistice Capital ("Armistice"). Armistice has invested $5 million in the form of a three-year senior secured note. This investment by Armistice has been made in conjunction with the company's licensing of Tuzistra® XR and a complementary antitussive pending FDA approval and is intended to further support the growth of the company's commercial portfolio.
- ACCESSWIRE•3 months ago
Aytu BioScience Announces Positive Interim Results from Natesto(R) Spermatogenesis Study
Fertility Preserved in Hypogonadal Men Taking Natesto, Based on Semen Analyses Conducted at Three-Month and Six-Month Timepoints ENGLEWOOD, CO / ACCESSWIRE / November 15, 2018 / Aytu BioScience, Inc. (NASDAQ: ...
- ACCESSWIRE•3 months ago
Aytu BioScience to Report Interim Results from Natesto(R) Spermatogenesis Study on Thursday, November 15, 2018
Live Conference Call and Webcast Scheduled for 5:00 p.m. ET on November 15, 2018 Presentation of Interim Analysis by Dr. Ranjith Ramasamy, MD, Director of Reproductive Urology and Assistant Professor, ...
- ACCESSWIRE•3 months ago
Aytu BioScience Reports 55% Sequential Revenue Growth in Q1 FY19; Adds Tuzistra(R) XR to Portfolio
Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE / November 7, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization ...
- ACCESSWIRE•3 months ago
Biotech Stocks and the Midterm Elections
HENDERSON, NV / ACCESSWIRE / November 7, 2018 / Midterm elections are expected to result in a split Congress, which should increase predictability for the biotech industry, and prevent, what some see as disruptive, government dictated pricing, less likely than if there is a Congress controlled by one party. Propanc Biopharma, Inc. (PPCB) is one biotech firm you should look at today. The FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer.
- ACCESSWIRE•3 months ago
Aytu BioScience Enters $3 Billion Cough and Cold Market and Expands Primary Care Portfolio, with Exclusive U.S. Licensing of Revenue-Generating, FDA-Approved Antitussive Tuzistra(R) XR
ENGLEWOOD, CO / ACCESSWIRE / November 5, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the Company's entry into the $3 billion cough and cold market with an exclusive license of FDA-approved Tuzistra® XR from Tris Pharma. Tuzistra XR is the only FDA-approved 12-hour codeine-based antitussive.
- ACCESSWIRE•4 months ago
Aytu BioScience to Report Fiscal First Quarter 2019 Results and Business Update
Live Conference Call and Webcast Scheduled for November 7, 2018, at 4:30 p.m. ET ENGLEWOOD, CO / ACCESSWIRE / October 31, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company ...
- American City Business Journals•4 months ago
These 16 public Colorado companies are concerned about tariffs, according to recent SEC filings
While these companies might not've spoken out publicly on the topic of tariffs, they have noted their concerns in SEC filings.
- ACCESSWIRE•4 months ago
Aytu BioScience Announces Issuance of First U.S. Patent Covering MiOXSYS(R) for Male Infertility; Company Progresses Toward U.S. Regulatory Clearance and Commercialization
U.S. Patent Number 10,088,466 is Company's First United States Patent Covering MiOXSYS for Male Infertility Assessment ENGLEWOOD, CO / ACCESSWIRE / October 11, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), ...
- ACCESSWIRE•4 months ago
Aytu BioScience Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
ENGLEWOOD, CO / ACCESSWIRE / October 10, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the closing of an underwritten public offering on October 9, 2018, with total gross proceeds of $15.2 million which includes the full exercise of the underwriters' over-allotment option to purchase additional shares and warrants, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) an aggregate of 457,007 shares of its Common Stock, (ii) an aggregate of 8,342,993 shares of its Series C Convertible Preferred Stock convertible into an aggregate of 8,342,993 shares of Common Stock at a conversion price of $1.50 per share, and (iii) Warrants to purchase an aggregate of 8,800,000 shares of Common Stock at an exercise price of $1.50 per share.
- ACCESSWIRE•4 months ago
Aytu BioScience Announces Pricing of $13.2 Million Underwritten Public Offering
ENGLEWOOD, CO / ACCESSWIRE / October 5, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the pricing of an underwritten public offering with expected total gross proceeds of $13.2 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) an aggregate of 457,007 shares of its Common Stock, (ii) an aggregate of 8,342,993 shares of its Series C Convertible Preferred Stock convertible into an aggregate of 8,342,993 shares of Common Stock at a conversion price of $1.50 per share, and (iii) Warrants to purchase an aggregate of 8,800,000 shares of Common Stock at an exercise price of $1.50 per share.
- ACCESSWIRE•5 months ago
Today’s Research Reports on Stocks to Watch: Aytu Bioscience and Altimmune
NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Shares of Altimmune were collapsing in Friday’s session as the company announced the pricing of an underwritten public offering. Shares of Aytu Biosciences were seeing gains of over 13% despite any significant news. Aytu BioScience, Inc. shares were up 13.11% on Friday on nearly 2.8 million shares traded.
- ACCESSWIRE•5 months ago
Today’s Research Reports on Stocks to Watch: Corbus Pharmaceuticals and Aytu Bioscience
NEW YORK, NY / ACCESSWIRE / September 21, 2018 / Biotech stocks Corbus Pharmaceuticals and Aytu BiosScience were both roaring on Thursday. Shares of Corbus exploded on the news that it has expanded its target indications by adding over 600 compounds that are focused on the endocannabinoid system from Jenrin Discovery. Aytu BioScience didn’t have any news yesterday but earlier in the week provided a clinical trial update.
- ACCESSWIRE•5 months ago
Aytu BioScience Announces Publication of Manuscript Summarizing Results from the Ongoing Natesto(R) Spermatogenesis Study
ENGLEWOOD, CO / ACCESSWIRE / September 17, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the publication of a clinical trial update in the journal European Urology Focus on the effects of Natesto® on reproductive hormones and semen parameters. This study is being conducted at the University of Miami's Department of Urology, and Dr. Ranjith Ramasamy, MD, the Director of Reproductive Urology, is the study's principal investigator. The publication entitled, "Natesto Effects on Reproductive Hormones and Semen Parameters: Results from an Ongoing Single-center, Investigator-initiated Phase IV Clinical Trial" provides updated data on five of the 23 currently enrolled subjects, through six months of Natesto treatment.
- ACCESSWIRE•5 months ago
Natesto(R) Q4 Revenue Increases 178% Sequentially; Q4 Product Revenue Increases 52% Sequentially
Highest Ever Quarterly Net Revenue for Natesto Testosterone Nasal Gel ENGLEWOOD, CO / ACCESSWIRE / September 6, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on ...
- ACCESSWIRE•6 months ago
Aytu BioScience to Report Fiscal Fourth Quarter 2018 Results and Business Update
Live Conference Call and Webcast Scheduled for September 6, 2018, at 4:30 p.m. ET ENGLEWOOD, CO / ACCESSWIRE / August 30, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company ...
